Brain volume loss, or atrophy, has been proven to be an important characteristic of neurological diseases such as Alzheimer's disease and multiple sclerosis. To use atrophy rate as a reliable clinical biomarker and to increase statistical power in clinical treatment trials, measurement variability needs to be minimized. Among other sources, systematic differences between different MR scanners are suspected to contribute to this variability. In this study we developed and performed initial validation tests of an MR-compatible phantom and analysis software for robust and reliable evaluation of the brain volume loss. The phantom contained three inflatable models of brain structures, i.e. cerebral hemisphere, putamen, and caudate nucleus. Softw...
In certain neuro-degenerative diseases likemultiple sclerosis (MS), the rate of brain atrophy can be...
MRI-derived rates of hippocampal atrophy may serve as surrogate markers of disease progression in mi...
MRI-derived rates of hippocampal atrophy may serve as surrogate markers of disease progression in mi...
Brain volume loss, or atrophy, has been proven to be an important characteristic of neurological dis...
A detailed analysis procedure is described for evaluating rates of volumetric change in brain struct...
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous sy...
OBJECTIVE: Brain atrophy is part of the pathophysiology of Multiple Sclerosis (MS), correlates with ...
BET (Brain Extraction Tool) is a widely used computer program to automatically separate brain from n...
We describe an improved method of measuring brain atrophy rates from serial MRI for multi-site imagi...
We present global and regional rates of brain atrophy measured on serially acquired Tl-weighted brai...
International audienceStructural MRI is widely used for investigating brain atrophy in many neurodeg...
BACKGROUND AND PURPOSE: Brain atrophy is a proposed marker of disease progression in multiple sclero...
AbstractStructural MRI is widely used for investigating brain atrophy in many neurodegenerative diso...
Objectives: Neurodegeneration in suspected Alzheimer’s disease can be determined using visual rating...
OBJECTIVES: To assess whether volumetric cerebrospinal fluid (CSF) MRI can be used as a surrogate fo...
In certain neuro-degenerative diseases likemultiple sclerosis (MS), the rate of brain atrophy can be...
MRI-derived rates of hippocampal atrophy may serve as surrogate markers of disease progression in mi...
MRI-derived rates of hippocampal atrophy may serve as surrogate markers of disease progression in mi...
Brain volume loss, or atrophy, has been proven to be an important characteristic of neurological dis...
A detailed analysis procedure is described for evaluating rates of volumetric change in brain struct...
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous sy...
OBJECTIVE: Brain atrophy is part of the pathophysiology of Multiple Sclerosis (MS), correlates with ...
BET (Brain Extraction Tool) is a widely used computer program to automatically separate brain from n...
We describe an improved method of measuring brain atrophy rates from serial MRI for multi-site imagi...
We present global and regional rates of brain atrophy measured on serially acquired Tl-weighted brai...
International audienceStructural MRI is widely used for investigating brain atrophy in many neurodeg...
BACKGROUND AND PURPOSE: Brain atrophy is a proposed marker of disease progression in multiple sclero...
AbstractStructural MRI is widely used for investigating brain atrophy in many neurodegenerative diso...
Objectives: Neurodegeneration in suspected Alzheimer’s disease can be determined using visual rating...
OBJECTIVES: To assess whether volumetric cerebrospinal fluid (CSF) MRI can be used as a surrogate fo...
In certain neuro-degenerative diseases likemultiple sclerosis (MS), the rate of brain atrophy can be...
MRI-derived rates of hippocampal atrophy may serve as surrogate markers of disease progression in mi...
MRI-derived rates of hippocampal atrophy may serve as surrogate markers of disease progression in mi...